Regenxbio
Develop innovative therapies to treat patients with rare or otherwise debilitating disease
Based in MD
🤖
AI Overview
With $665K in lobbying spend across 13 quarterly filings, Regenxbio is an active lobbying client. Their lobbying covers 4 issue areas. Active from 2021 to 2024.
$665K
Total Spend
4
Years Active
1
Firms Hired
1
Lobbyists Deployed
4
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2021 | $180K |
| 2022 | $240K |
| 2023 | $230K |
| 2024 | $15K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Medicare/Medicaid, Taxation, Health Issues, Pharmacy
- •Development of innovative therapies using gene therapy; biomedical research; Prescription drug user fee implementing legislation
- •Potential changes in the corporate tax rate or other provisions of interest to business (no specific bill)
- •Inclusion of provisions affecting the reimbursement of gene therapies that may be included in any drug pricing legislation or legislation on infrastructure (no specific bills)
- •Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)
Related Analysis
Related Investigations
The 22,000% ROI
When lobbying spending yields outsized returns.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.